Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 27;6(1):129–143. doi: 10.1002/acn3.687

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

The percent of plasmablasts after 1 week of IVIg treatment correlates with the rise in serum IgM and IgG levels. Serum IgM (A–C) and IgG (D–F) levels were determined before and after IVIg treatment and related to the percent of plasmablasts measured after 1 week of IVIg treatment. Absolute IgM/G levels are shown in A and D, the delta IgM/G levels at 1 week in B and E, and the delta IgM/G level at 2 weeks are indicated in C and F. Delta IgM/G levels were calculated compared to pretreatment levels, which were not available for all patients. Patients randomized for a second course of IVIg or placebo were excluded from analysis in C and F.